Pfizer Corporation

Wyeth

Zecheng Chen

Aranapakam Mudumbai Venkatesan

Christoph Martin Dehnhardt

Ariamala Gopalsamy

Arie Zask

David James Richard

Tarek Suhayl Mansour

Kevin Joseph Curran

Efren Guillermo Delos Santos

Jeroen Cunera Verheijen

Joshua Aaron Kaplan

Osvaldo Dos Santos

Mengxiao Shi

Semiramis Ayral-Kaloustian

Chakrapani Subramanyam

Andreas Maderna

Jeffrey Michael Casavant

Christopher John O'Donnell

Lawrence Nathan Tumey

Matthew David Doroski

Hud Lawrence Risley

Alexander M Porte

Semiramis Aryl-Kaloustian

Christopher John O'donnell

Christoph M Dehnhardt

Jeroen C Verheijen

The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula:F-L-T-L-Fwhere F, L, T, Land Fare as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.

Bifunctional cytotoxic agents containing the CTI pharmacophore

Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

Bifunctional cytotoxic agents

Compounds of formula I  and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Triazine compounds as PI3 kinase and mTOR inhibitors

Triazine compounds as PI3 kinase and MTOR inhibitors

Triazine compounds as P13 kinase and MTOR inhibitors

Compounds of formula I wherein:Ris and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Growing community of inventors

New City, NY, United States of America

Zecheng Chen